Aims We aimed to evaluate bleeding risk in clinical practice in patients with atrial fibrillation
(AF) being prescribed dabigatran, rivaroxaban, or apixaban compared with warfarin …

Background Non-vitamin K antagonist oral anticoagulants (NOACs) are at least as effective
and safe as vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF). All …

BACKGROUND: The use of non-vitamin K oral anticoagulants (NOACs) has increased
steadily following marketing approval; however, their relative safety in nonvalvular atrial …

Aims The introduction of direct oral anticoagulants (DOACs) has broadened the treatment
arsenal for nonvalvular atrial fibrillation, but observational studies on the benefit–risk …

Limited real-world data are available regarding the comparative safety of non-vitamin K
antagonist oral anticoagulants (NOACs). The objective of this retrospective claims …

Objective: To conduct a systematic review of real-world (RWD) studies comparing the risk of
major bleeding (MB) among patients with non-valvular atrial fibrillation (NVAF) on direct oral …

Background The nonvitamin K antagonist oral anticoagulants have recently become
available as an alternative to warfarin as stroke prophylaxis in atrial fibrillation, but data on …

Objective: To conduct a systematic literature review (SLR) and network meta-analysis (NMA)
of real-world studies comparing major bleeding risk among patients with non-valvular atrial …

Background Limited data are available about the real‐world safety of non‐vitamin K
antagonist oral anticoagulants (NOAC s). Objectives To compare the major bleeding risk …

Aims The aim of this study was to compare the risk of stroke or systemic embolism (SE) and
major bleeding in patients with atrial fibrillation (AF) using dabigatran, rivaroxaban, and …